Seeking Alpha

ImmunoCellular talks cancer vaccine program, shares rally

  • Shares of ImmunoCellular (IMUC) are trading sharply higher in premarket action.
  • Investors appear to be reacting to a press release out after the bell Monday in which the company said the first patient in a Phase 1 study of ICT-121 (another dendritic cell cancer vaccine) has received the treatment.
  • Notably, the company provides a bit of commentary on ICT-107 which, investors will recall, was behind a dramatic decline in IMUC's shares earlier this month when the OS K-M curves failed to hit statistical significance in a Phase 2 study.
  • IMUC says it "urges patients and other stakeholders to look beyond the unsubstantiated commentary on the recent trial results to what [the company] and clinical experts believe are important findings from this clinical program to date."
  • Further, IMUC says "nationally renowned neuro-oncologists ... share [the company's] view that as the survival data mature in 2014, there is the potential to see clarification of the survival benefit of the ICT-107 treated group." (PR)
  • IMUC +20% premarket
Comments (6)
  • jawdoc19@gmail.com
    , contributor
    Comments (37) | Send Message
     
    IMUC is no brainier at this level. Should quickly stabilize around 1.60-2.0
    24 Dec 2013, 08:56 AM Reply Like
  • BioDoubt
    , contributor
    Comments (16) | Send Message
     
    Translation: "Look beyond the fact that our drugs don't work and bid up our stock, we need to raise money soon."
    24 Dec 2013, 09:01 AM Reply Like
  • DonBerkowitz
    , contributor
    Comments (92) | Send Message
     
    "urges patients and other stakeholders to look beyond the unsubstantiated commentary on the recent trial results to what [the company] and clinical experts believe are important findings from this clinical program to date."

     

    It seems to me that investors have reacted reasonably to the substantiated results from the Phase II trial.

     

    Anyone considering an investment in IMUC should really do their homework now. Many articles on GBM candidates have mentioned a few of the competitors, but rarely do you see a comprehensive list of all or most of them. Here is a short list that I put together last week: CLDX, NWBO, DMPI, CYRX, CANF, NNVC. When IMUC's Phase II on 107 appeared to give them a leg-up, time-wise, on the competition, the stock was very interesting. Now, 107 is going nowhere without a lengthy and expensive Phase III, with only $30M in the bank. Meanwhile, all six of these other companies are or will be running trials and will be making news.

     

    ICT-121 is a long shot and may be promising, and 107 may also have value, but with the time element and the competition now in play, this is a very risky bet. Then, when you look at the market size, if you think IMUC is a great investment, you have to assume that some of these other competitors are not going to take a sizable share of that market. When IMUC was way ahead of the pack, the benefit from being first in terms of grabbing market share was a real plus. Now, that benefit is gone.

     

    Hopefully others will comment and shed further light on this list. Google and Seeking Alpha are your friends here - don't believe me - use them and reach your own conclusions.

     

    I am neither an investor nor short-seller in IMUC and have no plans to change that.
    24 Dec 2013, 09:24 AM Reply Like
  • toosmarttofail
    , contributor
    Comments (525) | Send Message
     
    I'm a sucker for beaten-down biotechs, at least as a flyer at $1.02, when I picked it after the drop. Now it's $1.0199.

     

    These companies rise from the ashes a lot more often than some might think.
    24 Dec 2013, 09:57 AM Reply Like
  • mikelazar
    , contributor
    Comments (232) | Send Message
     
    I think imuc could be a takeover target.
    24 Dec 2013, 02:51 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (525) | Send Message
     
    Charts don't lie; peoplo do.

     

    Ignore the news, follow the charts.
    26 Dec 2013, 09:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|